Prior to reperfusion therapy, the major therapeutic breakthrough in MI was the demonstration that ACE inhibitors, given to prevent adverse LV remodelling in high‐risk patients, reduced the likelihood of developing HF and the risk of death.5 This evidence concerns the gene ACE and hydrops fetalis.